XYLT2

Across TCGA pan-cancer cohorts, XYLT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated XYLT2 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher XYLT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated XYLT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where XYLT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.518	0.861	<.001	85	view →
HNSC	DFS	Median	IV	0.905	1.000	.029	14	view →
CCRCC	DFS	Tertile	All	1.000	0.677	.018	2	view →
LUAD	OS	Median	III,IV	0.876	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

XYLT2–PDAC (DFS)

Open the PDAC breakdown →